Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CDX-0158
i
Other names:
CDX-0158, CDX 0158, KTN-0158, KTN 0158, KTN0158
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Celldex
Drug class:
c-KIT inhibitor, mutant c-KIT inhibitor
Related drugs:
‹
dasatinib (215)
imatinib (166)
sunitinib (139)
lenvatinib (90)
YD312 (21)
ripretinib (11)
MLN518 (8)
SU5614 (6)
pexidartinib (6)
flumatinib (5)
ABT-869 (2)
AG-1296 (1)
IDRX-42 (1)
OSI-930 (1)
MP470 (1)
PLX9486 (1)
CS 2164 (1)
E7050 (1)
M4205 (0)
NB003 (0)
NMS-088 (0)
JSP191 (0)
AER-901 (0)
TSU-68 (0)
BAY 57- 9352 (0)
PTK787 (0)
avapritinib (13)
dasatinib (215)
imatinib (166)
sunitinib (139)
lenvatinib (90)
YD312 (21)
ripretinib (11)
MLN518 (8)
SU5614 (6)
pexidartinib (6)
flumatinib (5)
ABT-869 (2)
AG-1296 (1)
IDRX-42 (1)
OSI-930 (1)
MP470 (1)
PLX9486 (1)
CS 2164 (1)
E7050 (1)
M4205 (0)
NB003 (0)
NMS-088 (0)
JSP191 (0)
AER-901 (0)
TSU-68 (0)
BAY 57- 9352 (0)
PTK787 (0)
avapritinib (13)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors (NCT02642016)
Phase 1
Celldex Therapeutics
Celldex Therapeutics
Completed
Phase 1
Celldex Therapeutics
Completed
Last update posted :
06/12/2019
Initiation :
12/01/2015
Primary completion :
01/30/2018
Completion :
06/04/2019
KIT • PDGFRA
|
KIT positive • PDGFRA D842V • KIT expression
|
CDX-0158
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login